Back to top

Analyst Blog

Regado Biosciences, Inc. (RGDO - Snapshot Report), a clinical stage biopharmaceutical company, recently received  positive news when the U.S. Food and Drug Administration (FDA) accepted the company's investigational new drug (IND) application for REG2.

Regado is developing REG2, an extended release formulation of pegnivacogin, which is the prime component in company’s lead candidate REG1.

Regado is evaluating REG2 for potential uses in a wide range of acute and sub-acute care cardiovascular indications such as venous thromboembolism prophylaxis in patients undergoing abdominal surgery. Regado is also being evaluated as treatment for transcatheter aortic valve implantation (TAVI) patients and for bridging patients who are unable to take oral anticoagulants.

We note that Regado had previously completed a single escalating-dose phase I clinical trial on REG2. The company intends to conduct additional clinical testing in sub-acute venous thrombosis indications in future.

Meanwhile, Regado is evaluating lead candidate REG1 (consists of pegnivacogin, and anivamersen) as an anticoagulant for patients suffering from a variety of cardiovascular conditions and undergoing percutaneous coronary intervention (PCI).

PCI is a mechanical process to open or widen obstructed coronary arteries.

Regado’s prime focus is development of REG1 (in a phase III trial, REGULATE-PCI). The acceptance of IND for REG2 is a boost for the company’s pipeline. We expect investor focus to remain on REG1.

Regado currently carries a Zacks Rank #2 (Buy). Right now, investors may also consider Endocyte Inc. (ECYT - Snapshot Report), Actelion Ltd. (ALIOF) and Biogen Idec Inc. (BIIB - Analyst Report). All three carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 22.53 +4.50%
ERBA DIAGNO… ERB 2.91 +4.30%
PLANAR SYST… PLNR 4.31 +3.86%
MALLINCKROD… MNK 72.17 +3.83%
GTT COMMUNI… GTT 12.06 +3.52%